The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDunedin Ent.it. Regulatory News (DNE)

Share Price Information for Dunedin Ent.it. (DNE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 484.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 32.00 (6.838%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 484.00
DNE Live PriceLast checked at -
Dunedin Enterprise is an Investment Trust

To conduct an orderly realisation of its assets, to be effected in a manner that seeks to achieve a balance between maximising the value of the investments and progressively returning cash to Shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

6 Apr 2017 11:19

RNS Number : 8151B
Dunedin Enterprise Inv Trust PLC
06 April 2017
 

Dunedin Enterprise Investment Trust PLC (the "Company")

 

2016 Annual Report

 

Copies of the annual report and accounts for the year ended 31 December 2016 have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM and on the Company's website (www.dunedinenterprise.com).

 

The Disclosure Guidance and Transparency Rules (DTR 6.3.5(2)) require certain information to be disclosed upon publication of the annual report and accounts. Accordingly, in addition to the information set out in the announcement of the final results for the year ended 31 December 2016 on 20 March 2017, the following disclosures are made. References to page numbers and notes in the disclosures below are to page numbers and notes to the annual report and accounts of the Company for the year ended 31 December 2016:

 

Principal Risks and Uncertainties (Strategic Report pages 25-26)

The principal risks and uncertainties identified by the Board which might affect the Company's business model and future performance, and the steps taken with a view to their mitigation, are as follows:

 

Investment and liquidity risk: the Company's investments are in small and medium-sized unquoted companies, which by their nature entail a higher level of risk and lower liquidity than investments in large quoted companies. Mitigation: the Manager aims to limit the risk attaching to the portfolio as a whole by closely monitoring individual holdings, including the appointment of investor directors to the board of portfolio companies. The Board reviews the portfolio, including the schedule of projected exits, with the Manager on a regular basis with a view to ensuring that the orderly realisation process is progressing.

 

Portfolio concentration risk: following the adoption of the Company's revised investment policy in May 2016 the portfolio will become more concentrated as investments are realised and cash is returned to shareholders. This will increase the proportionate impact of changes in the value of individual investments on the value of the Company as a whole. The Directors' valuation of the Company's investments represents their best assessment of the fair value of the investments as at the valuation date and the amounts eventually realised from such investments may be more or less than the Directors' valuation. Mitigation: the Directors and Manager keep the changing composition of the portfolio under review and focus closely on those holdings which represent the largest proportion of total value.

 

Financial risk: most of the Company's investments involve a medium to long term commitment and many are relatively illiquid. Mitigation: the Directors consider it appropriate to finance the Company's activities through borrowing on a short-term basis. Accordingly, the Board seeks to ensure that the availability of cash reserves and bank borrowings match the forecast cash flows of the Company both on a base and stress case basis given the level of undraw commitments to limited partnership funds.

 

Economic risk: events such as economic recession or general fluctuations in stock markets and interest rates may affect the valuation of portfolio companies and their ability to access adequate financial resources, as well as affecting the Company's own share price and discount to net asset value. Mitigation: the Company invests in a diversified portfolio of investments spanning various sectors, and maintains access to sufficient cash reserves to be able to provide additional funding to portfolio companies should this become necessary.

 

Credit risk: the Company holds a number of financial instruments and cash deposits and is dependent on counterparties discharging their commitment. Mitigation: the Directors review the creditworthiness of the counterparties to these investments and cash deposits and seek to ensure there is no undue concentration of credit risk with any one party.

 

Currency risk: the Company is exposed to currency risk as a result of investing in companies and funds denominated in euros. The sterling value of these investments can be influenced by movements in foreign currency exchange rates. Mitigation: Currency risk is monitored by the Manager on an ongoing basis and on a quarterly basis by the Board.

 

Internal control risk: the Company's assets could be at risk in the absence of an appropriate internal control regime. Mitigation: the Board regularly reviews the system of internal controls, both financial and non-financial, operated by the Company and the Manager. These include controls designed to ensure that the Company's assets are safeguarded and that proper accounting records are maintained.

 

Related Party Transactions (Notes to the Accounts page 59, note 21)

The Company has investments in Dunedin Buyout Fund LP, Dunedin Buyout Fund II LP, Dunedin Buyout Fund III LP, Dunedin Fund of Funds LP and Equity Harvest Fund LP. Each of these limited partnerships are managed by Dunedin. The Company has paid a management fee of £2.2m (2015: £2.4m) in respect of these limited partnerships. The total investment management fee payable by the Company to the Manager is therefore £2.3m (2015: £2.5m).

 

A Manager's Incentive Scheme ("the Scheme") was introduced from 1 May 1999. Under the terms of the Scheme qualifying directors and investment executives of Dunedin were entitled to purchase 7.5% of the equity shares (and, occasionally, other financial instruments) in each of the directly held investments subscribed for by the Company. This scheme has now been replaced by the arrangements noted below.

 

Since the Company began investing in Dunedin Buyout Funds ("the Funds") executives of the Manager have been entitled to participate in a carried interest scheme via the Funds. Performance conditions are applied whereby any gains achieved through the carried interest scheme associated with the Funds are conditional upon a certain minimum return having been generated for the limited partner investors. Additionally, within Dunedin Buyout Fund II LP and Dunedin Buyout Fund III LP the economic interest of the Manager is aligned with that of the limited partner investors by co-investing in this fund.

 

As at 31 December 2016 there is a provision made within Investments for carried interest of £1.3m relating to Equity Harvest Fund LP and £0.2m relating to Dunedin Buyout Fund LP. Current executives of the Manager are entitled to 46% of the carried interest in Equity Harvest Fund LP and 60% in Dunedin Buyout Fund LP.

 

Brian Finlayson has an interest in the carried interest scheme of Dunedin Buyout Fund LP and received £nil from that scheme during 2016. Brian Finlayson was previously employed by the Manager and retired in 2002. As at 31 December 2016 the remaining value in this scheme attributable to Brian Finlayson is £3,874.

 

 

Enquiries

Graeme Murray Dunedin LLP T: 0131 225 6699

Sue Inglis Cantor Fitzgerald Europe T: 020 7894 8016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSUNARRBBASRAR
Date   Source Headline
22nd Mar 20247:00 amRNSAnnual Financial Report
5th Feb 20241:58 pmRNSHolding(s) in Company
5th Feb 20241:56 pmRNSHolding(s) in Company
5th Feb 20241:54 pmRNSHolding(s) in Company
1st Feb 20247:00 amRNSPreliminary Unaudited Net Asset Value at 31/12/23
19th Dec 20232:34 pmRNSHolding(s) in Company
19th Dec 20232:22 pmRNSHolding(s) in Company
13th Dec 20237:00 amRNSDividend Declaration
21st Nov 20237:00 amRNSPremier Hytemp realisation & potential winding-up
16th Nov 20237:00 amRNS3rd Quarter Results
6th Nov 20234:33 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSPortfolio Update
1st Nov 20237:00 amRNSPreliminary Unaudited Net Asset Value at 30/9/23
28th Sep 20237:00 amRNSPortfolio Update
15th Sep 20237:00 amRNSHalf-year Report
1st Aug 20237:00 amRNSPreliminary unaudited net asset value at 30/6/23
6th Jun 20239:01 amRNSHolding(s) in Company
22nd May 202310:05 amRNSHolding(s) in Company
10th May 20232:42 pmRNSResult of AGM
10th May 20232:42 pmRNS1st Quarter Results
2nd May 20237:00 amRNSPreliminary unaudited net asset value at 31/3/23
24th Mar 20237:00 amRNSAnnual Financial Report
1st Feb 20237:00 amRNSPreliminary Unaudited Net Asset Value at 31/12/22
7th Dec 20221:02 pmRNSDirector/PDMR Shareholding
7th Dec 20221:00 pmRNSDirector/PDMR Shareholding
7th Dec 20221:00 pmRNSDirector/PDMR Shareholding
6th Dec 202211:12 amRNSDirector/PDMR Shareholding
6th Dec 202211:09 amRNSDirector/PDMR Shareholding
1st Dec 202212:42 pmRNSHolding(s) in Company
30th Nov 20225:50 pmRNSDirector/PDMR Shareholding
30th Nov 20225:48 pmRNSDirector/PDMR Shareholding
30th Nov 202212:10 pmRNSHolding(s) in Company
29th Nov 20225:25 pmRNSHolding(s) in Company
29th Nov 202210:42 amRNSHolding(s) in Company
28th Nov 20229:06 amRNSHolding(s) in Company
25th Nov 20222:32 pmRNSHolding(s) in Company
22nd Nov 20227:00 amRNSResult of Tender Offer
16th Nov 202212:52 pmRNS3rd Quarter Results
16th Nov 202212:49 pmRNSResult of General Meeting
4th Nov 202210:00 amRNSHolding(s) in Company
4th Nov 20228:51 amRNSHolding(s) in Company
1st Nov 20227:00 amRNSQ3 Preliminary NAV and Tender Offer Price
21st Oct 20227:00 amRNSInterim Dividend
21st Oct 20227:00 amRNSTender Offer
7th Oct 20227:00 amRNSPortfolio Update
16th Sep 20227:00 amRNSHalf-year Report
25th Aug 20229:15 amRNSPortfolio Update
1st Aug 20227:00 amRNSPreliminary unaudited net asset value at 30/6/22
11th May 20222:58 pmRNSResult of AGM
11th May 20221:26 pmRNS1st Quarter Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.